DR. ANAND B. KARNAD, M.D.

Plain English
This study tested a combination treatment of lenvatinib and eribulin in patients with hard-to-treat solid tumors like breast and lung cancer. Out of 29 patients, 24% had a positive response to the treatment, with 29% of breast cancer patients and 33% of lung cancer patients showing improvement. Patients who did not express a protein called vimentin had better outcomes, and while there were some serious side effects reported, the overall treatment was manageable. Who this helps: This helps patients with advanced solid tumors, particularly those who have already undergone multiple treatments.

Plain English
Researchers studied a new treatment approach for high-risk diffuse large B-cell lymphoma (DLBCL) by combining a standard therapy called R-CHOP with a medication known as roflumilast. They found that after a follow-up of 44 months, 70% of patients were still alive and free of disease, and the combination appeared to be especially effective for patients with certain high-risk genetic types of DLBCL. This matters because it shows promise for improving outcomes in patients who currently have limited treatment options. Who this helps: This helps patients with high-risk DLBCL, particularly those with specific genetic subtypes.

Plain English
The study examined how pancreatic cancer cells develop resistance to a chemotherapy drug called gemcitabine. Researchers found that when they treated certain cancer cells with gemcitabine, the cells increased their levels of a protein called CD44, which made them resistant to the drug. Specifically, patients with high levels of CD44 and another protein, IGF1R, had worse outcomes, indicating that targeting these proteins could lead to better treatments for pancreatic cancer. Who this helps: This helps patients with pancreatic cancer by identifying potential targets for more effective therapies.

Plain English
This study looked at a new treatment called camidanlumab tesirine for patients with relapsed or hard-to-treat Hodgkin and non-Hodgkin lymphomas. Out of 133 patients, 71% with classical Hodgkin lymphoma showed a positive response to the treatment. The study highlights the potential of this drug to be an effective option for patients who have run out of other treatment choices. Who this helps: This research benefits patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma.

Plain English
This study investigated the effects of adding a drug called cetuximab to a combination of chemotherapy drugs (carboplatin and paclitaxel) in patients with advanced non-small-cell lung cancer (NSCLC) who had a specific genetic marker (EGFR FISH-positive). The research involved 1,313 patients and found that, overall, adding cetuximab did not improve how long patients lived or how long they survived without the disease getting worse. However, among patients with a certain type of cancer (squamous cell histology) who were EGFR FISH-positive, those taking cetuximab did live longer (about 10.9 months) compared to those who did not take it (about 9.2 months). Who this helps: Patients with advanced squamous cell NSCLC who are EGFR FISH-positive may benefit from cetuximab treatment.

Plain English
This study looked at a protein called CD44, which is found in high amounts in cancer cells, especially those that act like stem cells. Researchers found that CD44 has different forms, each playing a role in how cancer grows and spreads, including a variation that is present in tumors that have spread to other parts of the body. Understanding how CD44 works could lead to new treatments for cancer by targeting this protein. Who this helps: This helps patients with cancer by potentially offering new treatment options.

Plain English
This study looked at the effectiveness and safety of a new drug called alisertib, combined with existing treatments rituximab and vincristine, for patients with aggressive types of B-cell lymphoma that didn't respond to previous treatments. The researchers found that the best dose for combining alisertib with rituximab was 50 mg taken twice a day, and for the combination with both rituximab and vincristine, it was 40 mg. In total, 45 patients were tested, and about 45% of those receiving the combination treatment showed a positive response, including complete recovery in some cases, making this a promising option for tough-to-treat B-cell lymphoma. Who this helps: This helps patients with relapsed or refractory aggressive B-cell lymphoma.

Plain English
This study looked at how well 11 European countries are following heart health guidelines to prevent strokes. Researchers created a scorecard and found that while most countries have policies for general health, they are not doing enough to tackle stroke risks. Only about 30% of doctors are screening patients over 40 for high blood pressure, and even fewer are checking for a heart condition called atrial fibrillation in older patients. Who this helps: This helps patients at risk of stroke by promoting better screening and prevention strategies.

Plain English
This study looked at 170 cancer patients with liver problems to see if including those with severe liver dysfunction in early drug trials makes sense. It found that patients with severe liver dysfunction survived for only one month on average, compared to two months for the whole group; better survival was linked to better liver function and higher albumin levels. This matters because it highlights the need for better criteria, like albumin levels, to choose the right patients for these trials, ensuring that research is both safe and useful. Who this helps: Patients with liver dysfunction and those involved in clinical trials.

Plain English
This study looked at how a low dose of arsenic might help reduce the harmful effects of chemotherapy on blood cell production. Researchers found that when p53, a protein that usually makes cells vulnerable to chemotherapy damage, was temporarily suppressed using arsenic, patients had higher blood cell counts—specifically, white blood cells, hemoglobin, and neutrophils—compared to when p53 was active. This is important because it suggests a potential way to protect bone marrow from chemotherapy side effects, making treatment safer for patients. Who this helps: This helps cancer patients undergoing chemotherapy.

Plain English
Researchers studied how a protein called CD44 affects pancreatic cancer cells, particularly their ability to invade and resist chemotherapy. They found that cancer cells with high levels of a specific type of CD44 (called CD44s) are more aggressive and develop resistance to the drug gemcitabine. In tests, reducing CD44 levels made these cells more sensitive to the treatment and less invasive, indicating that targeting CD44 could improve treatment outcomes for patients. Who this helps: This helps patients with pancreatic cancer and their doctors by providing insights into potential new treatment strategies.

Plain English
This study looked at how patient navigation impacts the speed of breast cancer diagnosis after an abnormal screening test. Researchers found that while navigation didn't lead to quicker diagnoses at 60 or 180 days, it significantly improved timely diagnosis by 365 days, with patients being about 2.12 times more likely to receive prompt care. This is important because it shows that patient navigators can help ensure women, especially those from diverse and low-income backgrounds, get the care they need more efficiently. Who this helps: This helps women with abnormal breast cancer screenings, particularly those from minority and low-income groups.

Plain English
This study looked at two proteins, c-Met and RON, which are involved in how tumors grow and spread, and how they may lead to resistance against cancer treatments. Researchers found that both proteins are often more active in many types of tumors, which can worsen the disease. Encouragingly, new drugs that target these proteins are being tested, and using them alongside existing treatments could improve outcomes for patients. Who this helps: This helps cancer patients and doctors looking for more effective treatment options.

Plain English
This study looked at elderly cancer patients (70 years and older) who participated in early-phase clinical trials at a cancer center from 2009 to 2011. Out of 461 patients, only 15% were elderly, and they faced challenges like higher rates of other health issues compared to younger patients. The findings showed that 32% of the elderly completed at least 12 weeks of treatment, but they were more likely to stop due to disease progression or side effects. Who this helps: This helps elderly cancer patients by highlighting the need for clinical trials that better accommodate their specific health needs.

Plain English
This study looked at why Latino and other minority cancer patients in South Texas choose to participate or not in early-phase clinical trials, which are important for developing new cancer treatments. Researchers surveyed 100 patients and found that those who believe that the trial could improve their symptoms were 3.20 times more likely to refuse enrollment, while fear of new treatments increased the odds of not joining by 3.60 times. The findings highlight the need for tailored support and communication to help more minority patients participate in these trials, ensuring that all patient groups benefit from new medical advancements. Who this helps: This helps patients, particularly those from Latino and minority backgrounds, as well as doctors and researchers working on clinical trials.

Plain English
The study focused on how to increase the participation of minority groups, particularly Hispanics, in cancer clinical trials. Researchers found that while Hispanics generally have lower cancer rates, certain types of tumors are more common in this population, highlighting the need for better representation in research. A new Minority Recruitment Plan was launched in March 2013 to increase the enrollment of minorities in these trials, particularly to address the needs of the local South Texas community. Who this helps: This benefits patients, especially those from minority backgrounds, by ensuring that cancer treatments are tested on diverse populations.

Plain English
This study looked at how a patient navigation program helped Hispanic women who had abnormalities in breast cancer screenings. The results showed that those who received navigation care started treatment faster—on average, 57 days after diagnosis compared to 74 days without navigation. This program is important because it helps reduce delays in cancer care for these women, which can make a big difference in their treatment outcomes. Who this helps: This helps Hispanic women diagnosed with breast abnormalities, as well as healthcare providers working with them.

Plain English
This study looked at the side effects of a group of cancer drugs called mTOR inhibitors. It found that while most side effects are mild, such as sores in the mouth and skin rashes, some can be serious, requiring regular checks on patients. Understanding these specific side effects is important because it helps doctors better manage patient care while using these newer treatments. Who this helps: This helps patients undergoing treatment for cancer and their doctors.

Plain English
This study looked at how insulin might contribute to the development of certain cancers, including endometrial, colorectal, and breast cancers. Researchers found that high levels of insulin, often linked to conditions like obesity and diabetes, can promote tumor growth by helping cells grow more quickly and preventing cell death. Encouragingly, lowering insulin levels through exercise, weight loss, and a high-fiber diet may reduce cancer risk and new medications that improve insulin sensitivity could also be important for cancer prevention. Who this helps: This helps patients with obesity, diabetes, and anyone concerned about cancer risk.

Plain English
This paper focuses on a physical examination technique called percussion, specifically in an area known as Traube's space, to help diagnose lung conditions like fluid buildup. When doctors find that this area is no longer resonant, it often indicates a pleural effusion, or fluid in the lung area. Understanding and using this technique highlights the importance of traditional hands-on medical practices, reminding future doctors that personal interaction is key in patient care. Who this helps: This benefits medical students and doctors by reinforcing essential examination skills.

Plain English
This study examined a rare case of a 20-year-old man with non-T-cell lymphoblastic lymphoma, which is a type of cancer. He had serious bone damage (osteolytic lesions) and high calcium levels in his blood (measured at 13.5 mg/dL), but no swollen lymph nodes. This finding is important because it highlights that high-grade lymphomas can present unusual symptoms that are often linked to other blood cancers. Who this helps: This information is beneficial for doctors treating lymphoma and helps them recognize less common symptoms in young patients.

Plain English
This study looked at a group of bacteria called beta-hemolytic streptococci taken from the respiratory tracts of patients to understand their types and how they relate to illness. Out of 69 patients, 15 had clear respiratory infections, with 13 of those infected by Group B beta-hemolytic streptococci. The research found that older patients (average age 68) were more affected by Group B, and these patients often had conditions like cerebrovascular disease, while others with different streptococci types were more likely to have cancer, particularly in the head and neck. Who this helps: This helps doctors identify bacterial infections in older patients and understand potential underlying health issues.

Plain English
This study examined 11 cases of pneumonia caused by Enterobacter bacteria, focusing on patients in a hospital setting. Out of these cases, five were fatal, and most of the patients were elderly with an average age of 65 and had chronic obstructive pulmonary disease (COPD). This research highlights the significance of Enterobacter as a serious threat for pneumonia in older adults with pre-existing lung conditions. Who this helps: Patients with COPD and their healthcare providers.

Plain English
This study focuses on a rare case of a stomach cancer that spread to both eyes at the same time. The patient experienced a significant improvement in their vision after receiving radiation therapy, highlighting how effective this treatment can be for people dealing with eye tumors caused by cancer. This is important because it shows that timely treatment can help reduce vision loss in these patients. Who this helps: This helps patients with metastatic eye tumors from other cancers.

Plain English
This study examines a case of a patient with chronic myeloid leukemia who developed a serious bloodstream infection caused by a rare bacterium called Corynebacterium minutissimum. This patient was in a severe stage of their cancer, known as blast crisis, and this is the first time such an infection has been reported in a patient with this condition. Understanding this kind of infection is important because it helps doctors recognize and treat unusual bacterial infections in cancer patients more effectively. Who this helps: This information benefits doctors and healthcare providers caring for patients with cancer.

Plain English
This study looked at five patients who developed pneumonia caused by a germ called Branhamella catarrhalis and had low levels of immune proteins known as immunoglobulins, which help fight infections. The researchers found that people with these deficiencies were more likely to get this type of pneumonia, highlighting the importance of normal immunoglobulin levels in protecting against it. This research matters because it helps identify vulnerable patients and informs better treatment strategies. Who this helps: Patients with immunoglobulin deficiencies and their doctors.

Plain English
Researchers studied how automated blood tests that measure red blood cell volume distribution width (RDW) and mean platelet volume (MPV) can help in diagnosing anemia (low red blood cell count) and thrombocytopenia (low platelet count). They found that RDW helps differentiate types of anemia, while MPV provides insights into how well platelets are produced, which is crucial for managing patients with low platelet counts. This matters because better diagnosis leads to more effective treatment for these conditions, improving patient care. Who this helps: This helps patients with anemia and low platelet counts.

Plain English
This study looked at pneumonia caused by certain bacteria in patients who are elderly, immunosuppressed, or hospitalized. It found that two common bacteria, Pseudomonas aeruginosa and Serratia marcescens, were often linked to more severe cases that resulted in higher death rates, especially in patients with bacteria in their bloodstream. In contrast, other bacteria like Escherichia coli and Klebsiella were more common in less severe cases. This matters because it highlights the importance of quickly identifying and treating different bacterial infections to improve outcomes for vulnerable patients. Who this helps: This benefits patients, especially the elderly and those with weakened immune systems.